Education
About Us
Working with TipRanks
Follow Us
Tyra Bioscience, Inc (TYRA)
:TYRA
TYRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.42 - $29.60
Previous CloseN/A
Volume80.11K
Average Volume (3M)296.29K
Market Cap
$586.55M
Enterprise Value$239.01M
Total Cash (Recent Filing)$318.94M
Total Debt (Recent Filing)$6.12M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Aug 07, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding53,177,990
10 Day Avg. Volume217,348
30 Day Avg. Volume296,287
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.90K
Enterprise Value/Ebitda-2.11
Forecast
1Y Price Target
$30.20Price Target Upside173.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTYRA-300 led to an impressive 55% ORR in FGFR3+ mUC patients dosed with >90mg, which is significantly higher than erda's ~35% ORR.
Economic IncentivesThere may be an important economic incentive for community urologists to prescribe TYRA-300, as it may be prescribed through a popular group purchasing organization, called UroGPO.
Market PositionTYRA-300 should offer a unique competitive angle in NMIBC, if it is ultimately successful in clinical development.
Bears Say
Efficacy ComparisonThe delta between the 35% overall response rate for Balversa and 55% for TYRA-300 is quite wide, implying a wide margin for positive data.
RegulatoryManagement announced FDA acceptance of an IND for a Phase II study of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer, which will enroll up to 90 participants throughout the US.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience, Inc’s price range in the past 12 months?
Tyra Bioscience, Inc lowest stock price was $6.42 and its highest was $29.60 in the past 12 months.
What is Tyra Bioscience, Inc’s market cap?
Tyra Bioscience, Inc’s market cap is $586.55M.
When is Tyra Bioscience, Inc’s upcoming earnings report date?
Tyra Bioscience, Inc’s upcoming earnings report date is Aug 07, 2025 which is 2 days ago.
How were Tyra Bioscience, Inc’s earnings last quarter?
Tyra Bioscience, Inc released its earnings results on May 08, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.486 by $0.016.
Is Tyra Bioscience, Inc overvalued?
According to Wall Street analysts Tyra Bioscience, Inc’s price is currently Undervalued.
Does Tyra Bioscience, Inc pay dividends?
Tyra Bioscience, Inc does not currently pay dividends.
What is Tyra Bioscience, Inc’s EPS estimate?
Tyra Bioscience, Inc’s EPS estimate is -0.53.
How many shares outstanding does Tyra Bioscience, Inc have?
Tyra Bioscience, Inc has 53,177,990 shares outstanding.
What happened to Tyra Bioscience, Inc’s price movement after its last earnings report?
Tyra Bioscience, Inc reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.486. Following the earnings report the stock price went down -2.539%.
Which hedge fund is a major shareholder of Tyra Bioscience, Inc?
Currently, no hedge funds are holding shares in TYRA
Tyra Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.20 (173.80% Upside)
$30.20 (173.80% Upside)
Hedge Fund Trend
Increased
By 239.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $14.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-27.04%
Trailing 12-Months
Asset Growth
-15.14%
Trailing 12-Months
Company Description
Tyra Bioscience, Inc
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$30.20
▲(173.80% Upside)
Technical Analysis
Theravance Biopharma
―
SAGE Therapeutics
―
Mind Medicine
―
Meiragtx Holdings
―
Keros Therapeutics
―
Ownership Overview
50.21% Insiders
6.99% Mutual Funds
6.82% Other Institutional Investors
30.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---